CSI Market
Sign In | Register

Sonnet Biotherapeutics Holdings Inc (SONN) Quarterly Cash Flow Statement

Quarterly · GAAP · USD millions
Access SONN Annual Cash Flow →
Reviewing cash flow data across recent quarters allows users to assess how Sonnet Biotherapeutics Holdings Inc adapts its cash strategy across cycles.
View historic periods: Download as CSV:
Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.
Quarterly Report, GAAP in USD millions
ITEM 		(Sep 30 2025)
12 Months 		(Jun 30 2025) (Mar 31 2025) (Dec 31 2024) (Sep 30 2024)
Operating Activities
Income-16.01
Depreciation & amortization0.01
Amortization of Other Assets0.56
Extraordinary Item, Gain (Loss), Insurance Assets, Accretion Expense0.00
Restructuring & Impairment Charges0.00
Provision For Loan Losses Expensed0.00
Inventories Decrease /-Increase0.00
Research and Development in Process0.00
Gain (Loss) on Disposition of Assets0.00
Share-based Compensation0.20
Income (Loss) from Equity Method Investments0.00
Financial Instruments and Foreign Currency Transaction0.00
Other Than Temporary Impairment Losses Investments Portion Recognized In Earnings Net Availableforsale Securities-
Bad Debt Expense Related Party-
Income Loss Attributable To Noncontrolling Interest-
Investment Banking Advisory Brokerage And Underwriting Fees And Commissions-
Beneficial Coversion Feature Of Convertible Notes Payable-
Income Loss From Continuing Operations Including Portion Attributable To Noncontrolling Interest-
Proceeds From Issuance Of Common Stock For Sevices-
Income Loss Before Extraordinary Items And Cumulative Effect Of Change In Accounting Principle-
Amortization Of Warrants-
Common Stock And Warrants Issued For Interest-
Warrants Issued In Connection With Convertible Debt-
Amortization Of Operating Lease Assets-
Writeoff Investment-
Noncash Contribution Expenses-
Financing Costs Related To Chef Purchase Agreement-
Acquired Inprocess Research And Development0.11
Increase Decrease In Unbilled Collaboration Revenue-
Operating Lease Right Of Use Asset Amortization Expense0.16
Financing Costs-
Income taxes0.00
Losses/ -gains on Investments net0.00
Increase (Decrease) in Other Accounts Payable and Accrued Liabilities0.17
Increase (Decrease) in Accounts Payable0.63
Increase (Decrease) in Accrued Liabilities0.00
Deferred Revenue and Customer Advances and Deposits0.00
Increase (Decrease) in Prepaid Expense and Other Assets0.74
Other Working Capital-0.08
Other Noncash Expense0.00
Other net0.00
Payments for (Proceeds from) Other Operating Activities0.25
Discontinued operations0.00
Net Cash flow from Operating Activities-12.83
Investing Activities
Capital Expenditures0.00
Sale of Capital Items0.00
Short-term Investments Proceeds0.00
Short-term Investments Acq.0.00
Real Estate Investments0.00
Proceeds From Investment Distribution-
Initial Franchise Fees-
Proceeds From Tenant Improvement Allowances-
Restricted Cash and Investments Increase (Decrease)0.00
Payments for (Proceeds from) Loans0.00
Payments for (Proceeds from) Deposits0.00
Payments for (Proceeds from) Other Investments0.00
Payments for (Proceeds from) Federal Reserve and FHLB0.00
Payments to Acquire in Process Research and Development-0.01
Interest in Subsidiaries and Affiliates0.00
Sale of businesses0.00
Accounts payable0.00
Receivables0.00
Payments for (Proceeds from) Other Investing Activities0.00
Other Net0.00
Discontinued operations0.00
Net Cash Flow from Investing Activities-0.01
Financing Activities
Short-term debt Net0.00
Other borrowing transactions-0.47
Long-term debt - borrowings0.00
Long-term debt - repayments0.00
Federal Home Loan Bank and Federal Funds0.00
Issuances / -repurchases of Comm. Stock18.99
Partnership and Parent Transactions0.00
Issuances / -repurchases of Pref. Stock7.52
Deposits, Annuities, Contract Holders Funds0.00
Other financing activities net0.00
Other net-0.15
Proceeds From Issuance Of Common Stock And Warrants-
Increase Decrease In Other Liabilities-
Debt And Capital Lease Repayment-
Liabilities Subject To Compromise Increase Decrease In Other Liabilities-
Proceeds From Contributions From Subsidiary-
Decrease In Amounts Payable To Affiliate-
Contribution Of Non Controlling Intrest-
Expenses Related To Sale Of Preferred Stock-
Payments Related To Sale Of Preferred Stock-
Distributions To Noncontrolling Interest-
Contribution Of Noncontrolling Interest-
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations0.15
Proceeds From Issuance Of Common Stock And Warrants Net Of Issuance Costs-
Payments of Dividends, Preferred Stock and Preference Stock0.00
Dividends paid0.00
Net Cash Flow from Financing Activities26.05
Effect of exchange rate on cash flow0.00
Discontinued operations0.00
Free Cash Flow-12.83
Total Cash Flow13.21
4 historic quarters locked

Sign in to unlock the full Sonnet Biotherapeutics Holdings Inc cash flow history.

Sign In Create Free Account

About Sonnet Biotherapeutics Holdings Inc Quarterly Cash Flow Statement

What this statement shows

This page presents issuer-reported cash flow data, including operating, investing, financing, net, and free cash flow, as disclosed in SEC 10-Q filings and normalized by CSIMarket.

Source & verification

  • Form: 10-Q (Period: 20250630)
  • Filed with the SEC: August 13, 2025
  • Source: form10-q.htm

Last updated

  • Page updated:
  • Data lineage: SEC filings - XBRL extraction - normalization in the CSIMarket.com database.
  • Accession: 0001641172-25-023468

Figures are derived from filed reports and may be restated. Historical data is subject to revision.